Table 3. Main patient characteristics.
| Author, year, country | Treatment arms (number of episodes treated) | Age (min-max) years ± SD | Male/female | CD4 cell count (min-max) cells/mm3 | Antiretroviral therapy use (% of patients) | Previous AIDS diagnosis (% of patients) | % first VL episode | Follow up (interquartile range or standard deviation) in months | Lost to follow up (%) | Treated patients with parasitological test of cure (%) |
| Ritmeijer, 2011, Ethiopia | Liposomal amphotericin B (195) | μ = 30 (15–56) | 179/16 | X˜ = 155±123 | 42/87 (48.3) | NA | 59.5 | NA | 3/195 (1.5) | 129/195 (66.1) |
| Sinha, 2011, India | Liposomal amphotericin B (55) | μ = 35 (30–40) | 46/9 | μ = 66 (38–112) | 0/55 (0) | NA | 50.9 | x∼ 11.4 (3.4–20.3) | 0/55 (0) | 43/55 (78.2) |
| Molina, 2007, Spain | Liposomal amphotericin B (24) | μ = 36 (26–53) | 14/1 | x˜ = 100 (4–300) | 13/15 (86.7) | 7/12 (58.3) | 57 | x∼ 14 (5–44) | 2/24 (8.3) | 12/24 (50) |
| Ritmeijer, 2006, Ethiopia | Miltefosine (63) | x˜ = 33,4±9,5 | NA | NA | NA | NA | NA | 6 | NA | NA |
| Sodium stibogluconate (44) | ||||||||||
| Laguna, 2003, Spain | Amphotericin B lipid complex (17) | x˜ = 34,1±6 | 15/3 | x˜ = 41 (5–366) | 5/18 (27.8) | 10/18 (55.6) | 100 | 5 | 5/56 (8.9) | 43/56 (76.7) |
| Amphotericin B lipid complex (20) | x˜ = 33,7±5,8 | 17/3 | x˜ = 56 (0–731) | 13/20 (65) | 13/20 (65) | |||||
| Meglumine antimoniate (19) | x˜ = 34±5,2 | 16/3 | x˜ = 26 (1–600) | 7/19 (36.8) | 16/19 (84.2) | |||||
| Ritmeijer, 2001, Ethiopia | Generic sodium stibogluconate or Pentontan (27) | x˜ = 29,9 | 25/2 | NA | NA | NA | 100 | 6 | 1/27 (3.7) | 2/27 (7.4) |
| Pintado, 2001, Spain | Meglumine antimoniate (51) | x˜ = 33,2±8,2 | 64/16 | 32/80<200 | 19/80 (23.8) | 43/80 (53.8) | 100 | μ 13.8 (3–44) | NA | 30/51 (58.8) |
| Laguna, 1999, Spain | Meglumine antimoniate (44) | μ = 31 (19–64) | 40/4 | μ = 29 (1–203) | NA | 28/44 (63.6) | 100 | X∼ 10.8 | 6/89 (6.7) | 58/89 (65.2) |
| Amphotericin B deoxycholate (45) | μ = 32 (22–57) | 36/9 | μ = 18 (0–231) | 28/45 (62.2) | ||||||
| Behre, 1999, Ethiopia | Meglumine antimoniate (23) | x˜ = 28,6 (20–47) | 22/1 | NA | 0/23 (0) | NA | NA | NA | 0/23 (0) | 23/23 (100) |
| Delgado, 1999, Spain | Meglumine antimoniate (25) | x˜ = 30,2 (19–39) | 20/4 | x˜ = 66,2 (2–307) | 0/25 (0) | 17/24 (70.8) | 96 | 13.5 (0.25–26) | 1/25 (4) | 9/25 (36) |
| Lopéz-Veléz, 1998, Spain | Meglumine antimoniate (51) | x˜ = 31±7,5 | 46/8 | 33/54 <100 | NA | 25/54 (46.3) | NA | 6 | 0/51 (0) | 14/51 (27.4) |
| Laguna, 1997, Spain | Meglumine antimoniate (29) | NA | 42/1 | 34/43 <100 | 0/33 | 29/43 (67.4) | 70 | μ = 10.4 (2–25) | 3/33(9.1) | 23/33 (69.7) |
| Liposomal Amphotericin B (4) | ||||||||||
| Delgado, 1997, Spain | Meglumine antimoniate (21) | x˜ = 34,3±5,1 | 30/1 | x˜ = 37,9 (0–130) | NA | 18/31 (58) | 75.6 | μ = 10.9±8.5 | NA | 0 |
| Amphotericin B deoxycholate (20) | ||||||||||
| Russo, 1996, Spain, Portugal and Italy | Liposomal amphotericin B (10) | x˜ = 31,3 (25–43) | 9/1 | NA | NA | 5/10 (50) | 40 | μ = 12 | 0/10 (0) | 8/10 (80) |
| Ribera, 1996, Spain | Meglumine antimoniate (52) | x˜ = 28 (20–64) | NA | x˜ = 26,7 (2–268) | 37/52 (71.1) | 18/52 (34.6) | 71.7 | x˜ = 7.5 | 0/52 (0) | 26/52 (50) |
| Rosenthal, 1995, France | Meglumine antimoniate (27) | x˜ = 34 (22–68) | 42/8 | μ = 25 (0–200) | NA | 21/50 (42) | NA | NA | 5/41 (12.2) | 36/41 (87.8) |
| Amphotericin B deoxycholate (14) | ||||||||||
| Montalban, 1990, Spain | Meglumine antimoniate (40) | x˜ = 29,4 (20–53) | 36/4 | x˜ = 204,3±27,5 | NA | 19/40 (47.5) | NA | μ = 12,8 (0.5–71) | 0/40 (0) | 0 |
VL: visceral leishmaniasis NA: information not available x˜: median μ: mean SD: standard deviation.